We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioGenes Establishes Distribution Network for Generic HCP Assay in Major Markets
Product News

BioGenes Establishes Distribution Network for Generic HCP Assay in Major Markets

BioGenes Establishes Distribution Network for Generic HCP Assay in Major Markets
Product News

BioGenes Establishes Distribution Network for Generic HCP Assay in Major Markets


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "BioGenes Establishes Distribution Network for Generic HCP Assay in Major Markets"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioGenes GmbH has announced that it has signed long-term agreements with distributors in USA and Canada, India, Japan and Middle/South America to offer its enhanced generic HCP assay CHO|360-HCP ELISA within their respective territories. Europe and the rest of world (ROW) will be served by BioGenes directly.

CHO|360-HCP ELISA greatly improves the detection of HCPs in CHO cells by employing differently prepared host cell protein antigens and antibodies from two species. CHO|360-HCP ELISA allows users for the first time to easily choose the antibodies that work best for a specific process.

Dagmar Schwertner, Director of Marketing at BioGenes stated: “We are excited to partner with these premier distributors who will introduce CHO|360-HCP ELISA to their esteemed customer base. The distribution agreements will help leverage BioGenes’ sales and marketing capabilities to establish CHO|360-HCP ELISA as the preferred generic assay for HCP detection in CHO cells. BioGenes will be working closely with its distributors to ensure a high standard of service.”

Advertisement